Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyGlobeNewsWire • 08/19/24
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/24
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayGlobeNewsWire • 07/08/24
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160GlobeNewsWire • 06/27/24
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid ArthritisGlobeNewsWire • 06/14/24
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/30/24
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseGlobeNewsWire • 05/21/24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingGlobeNewsWire • 05/16/24
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 05/15/24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/24
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerGlobeNewsWire • 05/02/24
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's WhyZacks Investment Research • 04/10/24
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?Zacks Investment Research • 04/04/24
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 03/22/24
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should KnowZacks Investment Research • 03/19/24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/14/24
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorGlobeNewsWire • 03/11/24
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall StreetThe Motley Fool • 01/16/24
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024GlobeNewsWire • 01/08/24
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23